LILLY PROZAC SALES INCREASE 7% TO $580.7 MIL. IN THIRD QUARTER; PFIZER NORVASC SUPPLANTS PROCARDIA XL AS TOP PRODUCT WITH $899.8 MIL. YEAR-TO-DATE